CytomX Therapeutics
(NASDAQ) CTMX
CytomX Therapeutics Financials at a Glance
Market Cap
$831.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$35.54M
Net Income (TTM)
-$59.14M
EPS (TTM)
-$0.36
P/E Ratio
-10.50
Dividend
$0.00
Beta (Volatility)
1.16 (Average)
Dividend
$0.00
Beta (Volatility)
1.16 (Average)
Price
$3.80
Volume
3,200,230.331
Open
$3.76
Price
$3.80
Volume
3,200,230.331
Open
$3.76
Previous Close
$3.81
Daily Range
$3.70 - $3.89
52-Week Range
$1.72 - $8.21
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.16 (Average)
Price
$3.80
Volume
3,200,230.331
Open
$3.76
Previous Close
$3.81
Daily Range
$3.70 - $3.89
52-Week Range
$1.72 - $8.21
Estimated Earnings Date
Aug 6, 2026
CTMX News
CTMX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout CytomX Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
69
CEO
Sean A. McCarthy, PhD, MBA
Website
www.cytomx.comHeadquarters
South San Francisco, CA 94080, US
CTMX Financials
Key Financial Metrics (TTM)
Gross Margin
99.29%
Operating Margin
-181.92%
Net Income Margin
-166.40%
Return on Equity
-36.61%
Return on Capital
-21.66%
Return on Assets
-16.46%
Earnings Yield
-9.52%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$831.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
217.70M
Volume
3.20M
Avg. Volume
4.46M
Financials (TTM)
Gross Profit
$35.29M
Operating Income
-$64.66M
EBITDA
-$57.67M
Operating Cash Flow
-$80.09M
Capital Expenditure
-$101.00K
Free Cash Flow
-$80.19M
Cash & ST Invst.
$346.71M
Total Debt
$2.86M
CytomX Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$10.26M
-79.9%
Gross Profit
$10.01M
-80.3%
Gross Margin
97.55%
N/A
Market Cap
$831.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$6.99M
N/A
Employees
119
N/A
Net Income
-$18.25M
-177.6%
EBITDA
-$17.94M
-174.8%
Quarterly Fundamentals
Total Cash
$346.71M
+334.0%
Total Debt
$2.86M
-65.0%
Accounts Receivable
$646.00K
-67.0%
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$2.86M
-46.0%
Return on Assets
-16.46%
N/A
Return on Invested Capital
-19.87%
N/A
Free Cash Flow
-$25.55M
-20.7%
Operating Cash Flow
-$25.55M
-21.4%